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Hearing impairment and associated 
morphological changes in pituitary 
adenylate cyclase activating 
polypeptide (PACAP)-deficient mice
Daniel Balazs fulop1, Viktoria Humli  2, Judit Szepesy2, Virag ott1, Dora Reglodi1, 
Balazs Gaszner1, Adrienn nemeth1,3, Agnes Szirmai4, Laszlo tamas4, Hitoshi Hashimoto5,6,7, 
tibor Zelles2,8 & Andrea tamas1
pituitary adenylate cyclase activating polypeptide (pAcAp) is a regulatory and cytoprotective 
neuropeptide, its deficiency implies accelerated aging in mice. It is present in the auditory system 
having antiapoptotic effects. Expression of Ca2+-binding proteins and its PAC1 receptor differs in the 
inner ear of PACAP-deficient (KO) and wild-type (WT) mice. Our aim was to elucidate the functional 
role of PACAP in the auditory system. Auditory brainstem response (ABR) tests found higher hearing 
thresholds in KO mice at click and low frequency burst stimuli. Hearing impairment at higher 
frequencies showed as reduced ABR wave amplitudes and latencies in KO animals. Increase in neuronal 
activity, demonstrated by c-Fos immunolabeling, was lower in KO mice after noise exposure in the 
ventral and dorsal cochlear nuclei. Noise induced neuronal activation was similar in further relay nuclei 
of the auditory pathway of WT and KO mice. Based on the similar inflammatory and angiogenic protein 
profile data from cochlear duct lysates, neither inflammation nor disturbed angiogenesis, as potential 
pathological components in sensorineural hearing losses, seem to be involved in the pathomechanism 
of the presented functional and morphological changes in PACAP KO mice. The hearing impairment is 
probably concomitant with the markedly accelerated aging processes in these animals.
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide, member of the VIP/gluca-
gon/secretin peptide family showing 68% homology with VIP (vasoactive intestinal peptide). PACAP 
occurs in two biological active forms, PACAP38 containing 38 amino acids, and PACAP27 consisting of 
the N-terminal 27 amino acid residue of PACAP381. PACAP has its specific PAC1 receptor, and it also 
exerts its effects through VPAC1 and VPAC2 receptors which bind PACAP and VIP with equal affinity2. 
PACAP is abundant in the central and peripheral nervous system having neurotrophic and neuroprotec-
tive effects3,4. It is protective in different neurodegenerative and cerebral ischemia models5–7. PACAP is 
also present in several organs exerting antiapoptotic, cytoprotective and regulatory functions2. These reg-
ulatory functions in basic physiological processes are also supported by its evolutionary well-conserved 
sequence among species2,8. PACAP and its receptors are expressed in neuroepithelial cells at an early stage 
of ontogenesis9. It is also known that PACAP affects the development of several other cell types besides 
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neurons, e.g. retinoblasts and cells of the olfactory system, indicating that PACAP has important functions 
in different sensory organs10,11. It has well-known retinoprotective effects in different lesions of the retina, 
which were described morphologically, functionally and at the molecular level12–14. PACAP exerts protective 
functions in the olfactory system15. PACAP has also been described in several parts of the auditory sys-
tem16. Briefly, PACAP and PAC1 receptor are present in hair cells, supporting cells, spiral ganglion neurons, 
afferent and efferent nerve fibres, in the stria vascularis of the cochlea17–20 and in the nuclei of the auditory 
pathway21,22. Our previous in vitro experiments showed that PACAP protects the inner ear hair cells in case 
of oxidative stress. In a chicken inner ear cell culture, we applied H2O2 to induce reactive oxygen species 
production and we found that the number of living cells was higher and the apoptosis rate lower in case of 
PACAP co-treatment compared to the control H2O2-treated group23. We also performed in vivo studies on 
PACAP-deficient mice (KO)24. Based on developmental functions of PACAP, there are disturbances during 
the ontogenesis of PACAP-deficient mice compared to wild type (WT) mice and plasticity after injury is also 
disturbed. PACAP KO mice have no macroscopic differences compared to WT mice, however, they show 
biochemical changes25, behavioural alterations26,27, memory disorders28 and reduced fertility29,30. There are 
differences in several organ systems, as abnormal axonal arborization in the brain31, altered bone and car-
tilage formation32 and tooth development33,34. They show higher vulnerability after injuries in the brain, 
internal organs and the retina35–37. Intraperitoneal nitroglycerol treatment results in reduced meningeal 
blood flow elevation in PACAP KO animals confirming that PACAP is an important mediator of migraine38. 
The lack of endogenous PACAP also leads to accelerated aging in several organ systems39,40. For example ele-
vated corneal angiogenesis, accelerated aging of the retina, more severe systemic amyloidosis and impaired 
antioxidant capacity were found in PACAP KO animals39,41,42. We hypothesize that proteins and cytokines 
playing important roles in angiogenesis [acidic fibroblast growth factor (FGF), C-X-C motif chemokine 12 
(CXCL12), endostatin, Serpin F1], inflammatory processes [B lymphocyte chemoattractant (BLC), platelet 
factor 4 (PF4), CXCL12] and in coagulation [PF4, tissue factor (TF)] could also play an important role in 
the inner ear functions. Our previous experiments in PACAP-deficient mice showed that the expression 
of PAC1 receptor in the hair cells and outer phalangeal cells is decreased compared to WT mice17. There 
was an elevation in Ca2+-binding protein levels in inner ear hair cells of PACAP KO animals under normal 
circumstances compared to WT animals that could not be increased by ototoxic kanamycin treatment. 
These alterations indicate pathological deterioration in PACAP KO animals17,43. In our current study, we 
elucidated the functional outcome of PACAP deficiency on hearing and attempted to clarify some of the 
underlying molecular mechanisms. We measured in WT and PACAP-deficient mice the hearing thresholds, 
amplitudes and latencies of auditory brainstem responses (ABRs); quantified the neuronal activation in 
the nuclei of the auditory pathway after acoustic stimulation; and performed proteome profile analysis of 
cochlear duct lysates to explore the molecular mechanisms of the impairing effect of endogenous PACAP 
deficiency on hearing.
Results
In vivo ABR recordings – Hearing thresholds. PACAP KO mice had significantly higher hearing thresh-
olds at click and at low frequency burst stimuli – 4.1 kHz and 8.2 kHz – at the age of 1.5 months (Fig. 1, Table 1). 
This represents a massive hearing deficit in PACAP KO mice compared to the WT animals. We repeated the ABR 
measurements at the age of 4 and 8 months (Fig. 1/b, Table 1). The auditory thresholds were further elevated at 
lower frequencies in older PACAP KO mice, however, the WT mice also reached a plateau with aging. Therefore, 
the difference between the two groups was less pronounced (Fig. 1/b, Table 1). At higher frequencies, we did not 
find differences in the hearing thresholds between the two groups at either age.
In vivo ABR recordings – Analysis of peak amplitudes and latencies. We analysed the ABR wave 
amplitudes and latencies in 1.5-month-old mice at all measured stimulus intensity levels to explore further differ-
ences between the PACAP KO and WT mice at higher frequencies (16.4, 32.8 and 65.6 kHz) where there were no 
differences in the hearing thresholds (Figs 2, 3). All WT and PACAP KO mice were analysed, but not all 5 peaks 
appeared at each frequency at each sound pressure level [e.g. peak I at 16.4 kHz presented only in one WT mice at 
30 dB sound pressure level (SPL), while in 29 WT mice at 90 dB SPL]. There was a significant decrease in the ABR 
peak amplitudes of PACAP KO mice on peaks I-II and IV-V at high stimulus intensity (Fig. 2, for P values please 
see Supplementary Table S1). The latencies were also tendentially shorter at high frequencies in all peaks and the 
differences were significant in several cases (Fig. 3, for P values please see Supplementary Table S1). Differences are 
easily recognizable visually on the superimposed average curves of ABR waves of the PACAP KO and WT mice at 
32.8 and 65.6 kHz (Figs 2/c and 3/c). We often observed the fusion of peaks III and IV in both WT and PACAP KO 
animals. However, this merge occurred more frequently in PACAP KO mice, as it is shown by the lower incidence 
of peak IV in these mice at 16.4, 32.8 and 65.6 kHz at higher stimulus intensities (Fig. 4, Supplementary Table S1).
Auditory pathway activation and cell count measurement – c-Fos immunolabeling, Nissl staining. 
We examined the neuronal activation with c-Fos immunoreactivity in the auditory pathway (Figs 5, 6, Table 2). 
In the ventral cochlear nucleus (VCN), there was almost no cell activation in mice, which were held in a silent 
environment for 24 hours before termination (labelled as ‘silent’). There was a significant elevation of activated 
neurons in both WT and PACAP KO animals after exposure to half an hour filtered white noise. The elevation 
was significantly smaller in KO animals compared to WT ones (Fig. 5/a,b, Table 2). We found similar results 
in the dorsal cochlear nucleus (DCN) with almost no cell activation in the silent environment and significant 
elevation in the number of activated neurons after noise application both in WT and PACAP KO animals. The 
elevation was significantly smaller in KO animals compared to WT animals (Fig. 5/a,c, Table 2). We applied Nissl 
staining to the slides of VCN and DCN of WT and PACAP KO animals to decide whether a decreased number of 
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cells had caused the reduced c-Fos immunopositivity in PACAP KO animals. Despite the different cell activation 
with c-Fos immunostaining there was no difference in cell number in the VCN and DCN between the WT and 
PACAP KO animals (WT = 149.88 ± 18.99 and KO = 159.50 ± 8.00) (Fig. 5/d,e).
Figure 1. Hearing threshold measurements with auditory brainstem response (ABR) tests in wild-type (WT) 
and PACAP-deficient (KO) mice. (a) Individual curves of evoked potentials (click stimuli) in 1.5-month-old 
mice. Hearing threshold at 20 dB sound pressure in WT (black arrow) and at 60 dB sound pressure in KO 
mice (red arrow). ABR peaks I-V labelled at 80 dB WT curve: peak I arising from the cochlea/spiral ganglion 
neurons, peaks II-V arising from upper nuclei of the auditory pathway. (b) Hearing thresholds in WT and 
KO mice with click stimuli and at different frequencies at the age of 1.5, 4 and 8 months. Asterisks indicate 
significant differences between KO and WT mice. Mean ± SEM, 2-way-ANOVA, Bonferroni post-hoc test. 
****p < 0.0001, **p < 0.01, *p < 0.05 vs. WT values at the corresponding stimulus frequency.
4Scientific RepoRtS |         (2019) 9:14598  | https://doi.org/10.1038/s41598-019-50775-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
The differences between the WT and KO animals disappeared in the central parts of the auditory pathway 
(Fig. 6). There was a small neuronal activation in the silent group regarding the medial superior olive (MSO) and 
lateral superior olive (LSO) parts of the superior olivary complex (SOC) in both WT and PACAP KO animals. 
We found significant elevation of c-Fos immunolabeling in both WT and PACAP KO animals after noise appli-
cation but there was no significant difference between the WT and PACAP KO groups (Fig. 6/a, Table 2). We also 
measured the number of activated cells in the region of ventromedial and ventrolateral periolivary nuclei (VMPN 
and VLPN, respectively) with similar results. Noise application resulted in an elevation of activated neurons in 
both WT and PACAP KO animals but there was no difference between the WT and PACAP KO groups (Fig. 6/a, 
Table 2). The nuclei of the lateral lemniscus (NLL) yielded similar results: we measured neuronal activation in the 
silent animal groups that was significantly elevated after noise application but there was no difference between the 
WT and PACAP KO groups (Fig. 6/b, Table 2). We also found in the inferior colliculus (IC) a baseline cell activa-
tion in silent animal groups which elevated significantly after noise application again with no difference between 
the WT and PACAP KO groups (Fig. 6/c, Table 2). In the primary auditory cortex, the neuronal activation in the 
silent animal groups showed a tendency to be elevated after noise application but this elevation was not signifi-
cant. There was no significant difference between the WT and PACAP KO animals (Fig. 6/d, Table 2). Without 
significant differences in the number of activated neurons, we did not perform Nissl staining in these nuclei.
Cochlear duct proteome profile analysis. We used Proteome Profilers from the R&D Systems to eluci-
date the protein composition of the cochlear ducts of WT and PACAP KO mice (Figs 7, 8). The Mouse Cytokine 
Array Panel A and the Mouse Angiogenesis Array Kits are eligible to detect 40 and 53 different proteins, respec-
tively. From the lysates of cochlear ducts endostatin, acidic FGF, osteopontin, BLC, CD54, PF4, TF, DPPIV, 
IGFBP-2, Serpin F1 and CXCL12 were in detectable quantity. The pixel density of the respective spots did not 
show significant differences between the WT and PACAP KO groups (Fig. 8, Supplementary Table S2).
Discussion
Hearing impairment is a disease affecting approximately 500 million people worldwide. Hearing loss could be 
of various origins, including genetic disorders, intrauterine damage, contagious diseases, noise trauma, aging or 
toxic agents44. After our earlier studies in the inner ear, our present study further elucidates the role of endoge-
nous PACAP in the auditory pathway and could lead to further investigations on the use of PACAP in different 
auditory system deficiencies.
The presence of PACAP has been demonstrated in the nuclei of the auditory pathway. It is present in the cell 
bodies and fibres of cochlear nuclei, with higher expression in the VCN21,22. It has been found in different nuclei 
of the SOC in rat and Djungarian hamsters, being described in the perikarya of medial nucleus of the trapezoid 
body, MSO, LSO and periolivary nuclei, including the nuclei of the olivocochlear fibres which could be the source 
of PACAP positive fibres in the cochlea22,45. PACAP was found in the medial olivocochlear tract ending on the 
outer hair cells but not in the lateral olivocochlear tract, which terminates on the dendrites of the spiral ganglion 
neurons under the inner hair cells. This confirms the theory that PACAP has a greater role in the efferent than 
in the afferent innervation of the cochlea19. PACAP was also found in the IC and medial geniculate body in rat 
and human brains21,46. PAC1 receptor mRNA expression was found in VCN, DCN, SOC, NLL, IC and medial 
geniculate body in the rat brain47–49. Human studies showed no PAC1 receptor expression in the IC under normal 
circumstances but its weak expression was present in sudden infant death syndrome brain samples50.
Based on these results, we examined the changes of the hearing function in PACAP KO animals. We found 
with ABR hearing threshold tests that PACAP KO mice have a significantly worse hearing with click stimuli and 
at 4.1 and 8.2 kHz frequencies compared to the WT ones at 1.5 and 4 months of age but there are no differences in 
the hearing thresholds at higher frequencies. At 8 months of age, the difference was significant at click and 4.1 kHz 
burst stimuli. With the evaluation of the hearing thresholds, it has to be taken into account that the CD1 mouse 
strain is subject to age related hearing loss. The hearing threshold pattern found in our experiments coincides 
with earlier described patterns characteristic for CD1 mice51. This could be the reason that there is no difference 
in the hearing threshold at higher frequencies and cause the disappearance of the significance at 8.2 kHz between 
the PACAP KO and WT mice at the age of 8 months. Although PACAP KO animals have no obvious deficit in 
hearing thresholds compared to WT animals in the higher frequency range tested (16.4; 32.8 and 65.6 kHz), 
amplitude and latency examinations revealed altered hearing functions at these frequencies. The amplitudes – in 
Age Stimulus WT (Mean ± SEM) KO (Mean ± SEM) p value
1.5 months click 25 ± 2.33 dB 54.62 ± 3.15 dB p < 0.0001
1.5 months 4.1 kHz 33.1 ± 2.33 dB 66.92 ± 3.5 dB p < 0.0001
1.5 months 8.2 kHz 34.48 ± 3.04 dB 65 ± 2.9 dB p < 0.0001
4 months click 42.78 ± 3.31 dB 74.67 ± 2.74 dB p < 0.0001
4 months 4.1 kHz 43.89 ± 4.13 dB 81.33 ± 4.24 dB p < 0.0001
4 months 8.2 kHz 66.11 ± 3.44 dB 84.67 ± 2.15 dB p < 0.0001
8 months click 68.24 ± 3.12 dB 78.75 ± 1.25 dB p = 0.0364
8 months 4.1 kHz 75.29 ± 4.47 dB 88.75 ± 1.25 dB p = 0.003
8 months 8.2 kHz 88.24 ± 0.95 dB 85 ± 2.67 dB ns
Table 1. Results of hearing threshold measurements with auditory brainstem response (ABR) tests in wild-type 
(WT) and PACAP-deficient (KO) mice with different stimuli at 1.5, 4 and 8 months of age. ns = non-significant.
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line with the activation and firing of the neurons in the hearing pathway – of the PACAP KO mice showed a 
strong decrease compared to WT littermates. However, the latencies – the time of the response after the stimulus 
- of the PACAP-deficient mice showed a bit faster neuronal activation and transmission. Decreased amplitude 
and latency values are probably the subtle indications of hearing impairment not revealed by hearing threshold 
measurements52,53. During the analysis of individual waves, the labelling of the peaks of PACAP-deficient mice 
was often cumbersome because of peak fusions. In KO mice, we saw fusion of peaks III and IV, however, these 
ABR waves in WT animals were rather separated.
To confirm the functional findings, we performed c-Fos immunolabeling to show the neuronal activation of 
the nuclei of the auditory pathway. Unlike Fos-B, c-Fos is a short-term activation marker of nerve cells commonly 
used in the auditory pathway resulting in alterations at gene expression level54,55. The activation was achieved by 
applying 4 to 20 kHz noise with 100 dB sound pressure for half an hour for the mice. Several different setups could 
be used for c-Fos activation measurements in the auditory pathway56,57, however, in our model we allowed 1 hour 
for the expression and nuclear translocation of c-Fos.
In the VCN and DCN, we found very few c-Fos immunopositive cells in the silent environment in both 
groups. However, there were activated neurons both in the WT and PACAP KO animals after noise exposure but 
the activation was significantly smaller in the KO mice. These results correspond to the functional ABR findings. 
Regarding the central parts of the auditory pathway, there was baseline cell activation in the SOC, NLL, IC and 
primary auditory cortex (AU1). The number of activated cells was significantly elevated after noise exposure 
Figure 2. Genotype-dependent differences in the auditory brainstem response (ABR) amplitude-intensity 
profiles of PACAP-deficient (KO) and wild-type (WT) mice at 16.4, 32.8 and 65.6 kHz. (a) Asterisks indicate 
significant differences between KO and WT mice. Mean ± SEM; 2-way-ANOVA, Bonferroni post-hoc test. 
****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 vs. WT values at the corresponding stimulus frequency and 
intensity. (b) Example for absolute amplitude measurement at peak II. (c) Average traces (±SEM) at 32.8 kHz, 
90 dB demonstrate the waveform differences between WT and KO mice. Two-headed arrows (↕) demonstrate 
the difference between peak I amplitude values (black: WT, red: KO).
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in the SOC, NLL and IC in both genotype groups and elevation was also detected in the AU1 region but it was 
non-significant. However, we did not find any difference between the WT and PACAP KO groups. The significant 
differences between the silent and noise-exposed groups show that our measurements are valid and the lack of 
difference between the two genotypes does not result from a technical error. The reason for the baseline activation 
of neurons could arise from the fact that these nuclei are not simply relay stations of the auditory pathway but 
that they obtain afferentation from other brain areas and serve more complex functions. SOC receives innerva-
tion from IC, from thalamus, from AU1 and from serotonergic and noradrenergic centres; NLL from IC58,59. IC 
gains information from auditory and somatosensory cortices and from the somatosensory nuclei of the brain-
stem60. AU1 has a leading role in multimodal information processing61. These connections can explain the base-
line neuronal activity in the silent animal groups and the disappearance of the differences between the WT and 
KO animal groups. It has long been hypothesized that changes in other signalling pathways could play a role in 
compensating for the lack of PACAP in PACAP-deficient animals34,62. We assume that there is a greater possibility 
for this compensation in the central nuclei of the auditory pathway as those obtain more complex connection 
patterns with several neuronal types releasing numerous neurotransmitters in these areas.
To elucidate the cause of the impaired hearing functions we aimed to further explore the role of endogenous 
PACAP in the inner ear, and therefore we performed proteome profile analysis from cochlear duct lysates from 
WT and PACAP-deficient mice. As mentioned in the introduction, PACAP and its specific PAC1 receptor have 
Figure 3. Genotype-dependent differences in the auditory brainstem response (ABR) latency-intensity profiles 
of PACAP-deficient (KO) and wild-type (WT) mice at 16.4, 32.8 and 65.6 kHz. (a) Asterisks indicate significant 
differences between KO and WT mice. Mean ± SEM; 2-way-ANOVA, Bonferroni post-hoc test. **p < 0.01, 
*p < 0.05 vs. WT values at the corresponding stimulus frequency and intensity. (b) Example for absolute latency 
measurement at peak II. (c) Average traces (±SEM) at 65.6 kHz, 90 dB demonstrate the waveform and latency 
differences between WT and KO mice. Two-headed arrows (↔) demonstrate the difference between peak V 
latency values (black: WT, red: KO).
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been demonstrated earlier in several parts of the inner ear16. After showing that PACAP had antiapoptotic effects 
on inner ear cells in vitro23, our research group also demonstrated that the levels of Ca2+-binding proteins (par-
valbumin, calretinin, calbindin) are elevated in the hair cells of PACAP KO animals compared to WT ones17. We 
also described elevated Ca2+-binding protein levels in WT animals after ototoxic kanamycin treatment43. We 
suppose that the elevation of Ca2+-binding proteins in PACAP KO animals under normal circumstances could 
be a compensatory mechanism indicating pathological conditions in the inner ear. This pathology could be the 
result of the missing antiapoptotic and oxidative stress attenuating effects of PACAP in these animals. However, 
the baseline elevated Ca2+-binding protein levels in PACAP KO animals did not increase further after kanamycin 
treatment possibly indicating a limitation of this compensatory mechanism.
Inflammation63,64 and angiogenesis65 are known processes involved in different types of sensorineural hear-
ing loss. In this study, we investigated their role in hearing loss that developed in the absence of endogenous 
PACAP. The use of isolated cochlear duct lysates excludes the contamination by proteins from the bony coch-
lea. We detected the ubiquitous cell surface enzyme DPPIV, antiapoptotic osteopontin, intercellular adhesion 
molecule CD54 and several other proteins taking part in angiogenic (acidic FGF, CXCL12), antiangiogenic 
(endostatin, Serpin F1), chemotactic (BLC, PF4, CXCL12) and coagulation (PF4, TF) procedures in both WT and 
PACAP-deficient mice. However, we did not find significant differences in the expression of the measured pro-
teins between the two genotypes. We concluded that the differences in hearing between the WT and PACAP KO 
mice cannot be substantiated by alterations in the expression of the investigated proteins in the endolymphatic 
ducts. Results of the chosen proteome profiler kits do not support the involvement of inflammatory or angiogenic 
processes in the hearing impairment caused by the lack of PACAP.
It still remains an open question whether the hearing loss is caused by inner ear or auditory pathway lesions. It is 
known that isolated inner ear lesions also lead to complex changes in the auditory pathway. Besides the direct effect 
of the absence of neuronal activation in the nuclei of the auditory pathway, it could also lead to alterations in the 
tyrosine hydroxylase or Ca2+-binding protein expression66,67. The lesion of the inner ear alone could be the reason of 
the impaired hearing function and attenuated c-Fos expression in PACAP KO animals. Nissl staining also confirmed 
this, whereby in spite of the smaller number of activated c-Fos expressing neurons, the cell number of neurons in the 
VCN and DCN did not change significantly in PACAP KO animals compared to the WT ones.
We confirmed that CD1 mice have a progressive hearing loss by aging. This process involves the loss of inner and 
outer hair cells in the inner ear51. It is also known that aging processes are accelerated in PACAP KO mice affecting sev-
eral organ systems14,25,39–41. An acceptable hypothesis could be that the changes we found in the auditory system of the 
PACAP KO mice are the result of the accelerated aging of the inner ear and auditory pathway. The neuroprotective and 
general cytoprotective effects of PACAP are not present in PACAP KO animals that could be the cause for an increased 
hair cell loss and consequent impaired hearing functions. However, hearing loss and the accompanying hair cell dam-
age is present in the WT CD1 animals51, it could be only more expressively present in KO mice. This could be the reason 
why we did not detect significant differences in the proteome profile of WT and PACAP KO mice.
We conclude that endogenous PACAP is essential for normal hearing functions. The normal aging and the 
processes of hearing loss in the inner ear are accelerated in PACAP-deficient mice, but the exact mechanisms 
are yet to be elucidated. Still, the possibility arises that administration of PACAP or an agonist of its receptors 
may have a curative effect in age-related or noise-/ototoxic-drug-induced hearing loss, as we have already shown 
PACAP protection in another sensory system13,68. Therefore, we plan to elucidate the effects of ototoxic insults 
in PACAP KO animals and examine whether the impairments could be prevented by exogenous PACAP/agonist 
administration bringing us one step closer to reveal the curative effects of PACAP.
Materials and Methods
Animals. All the experiments were performed on male WT (CD1) and homozygous PACAP KO mice. 
Animals were fed and watered ad libitum, under light/dark cycles of 12/12 h. All procedures were performed in 
accordance with the ethical guidelines of the University of Pecs (approved by the Food Chain Safety and Animal 
Health Directorate, Government Office of Baranya County, Hungary, BA02/2000-24/2011) and Semmelweis 
Figure 4. Proportions (%) of separate auditory brainstem response (ABR) peak IV at increasing intensity levels 
at 16.4, 32.8 and 65.6 kHz tone burst stimuli. In wild-type (WT) mice, peak IV is more identifiable, than in 
PACAP-deficient (KO) mice. ‘N-1’ Chi-squared test, **p < 0.01, *p < 0.05 vs. WT values at the corresponding 
stimulus frequency and intensity.
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University (approved by the Food Chain Safety and Animal Health Directorate, Government Office of Pest 
County, Hungary, XIV-I-001/1028-4/2012; PE/EA/1912-7/2017). The PACAP KO mice were generated by 
Hashimoto and co-workers26. Maintaining of the in-house-bred animals included backcrossing for 10 generations 
with CD1 mice. For details on genotyping, please see Supplementary Information.
In vivo recordings of auditory brainstem responses (ABRs). In mice and humans alike, sound-evoked 
potentials from the auditory brainstem appear as a series of consecutive peaks and valleys of ABR waves. These 
peaks come from the synchronous synaptic activity of nuclei along the afferent auditory pathway (Fig. 1/a). 
The first peak arises from the cochlea / spiral ganglion neurons ~1 ms after the stimulus onset (latency). Peaks 
II-V arise from the upper nuclei (i.e. cochlear nuclei, medial nucleus of the trapezoid body, SOC and IC) of 
the auditory pathway69. ABR measurements were performed as described before70. Briefly: mice were anaesthe-
tized by intraperitoneal (i.p.) injections of ketamine (100 mg/kg, CP-Ketamin 10% injection, Produlab Pharma 
B.V., Netherland) and xylazine (10 mg/kg, CP-Xylazine 2% injection, Produlab Pharma B.V., Netherland). 
Ketamine-xylazine affects the results of ABR measurements compared to awake mice but it has less influence on 
Figure 5. Expression of c-Fos in the dorsal and ventral cochlear nuclei (DCN, VCN) of 1.5-month-old wild-
type (WT) and PACAP-deficient (KO) animals after noise exposure (noise) or without noise exposure (silent). 
(a) Representative images with lower and higher magnification of the VCN and DCN (rectangle in the low 
magnification picture) in frontal sections of the brainstem. Black line in ‘WT silent’ image represents the border 
between VCN (below) and DCN (above). (b,c) Number of c-Fos immunopositive cells in VCN and DCN, 
respectively. Noise application caused a significant elevation of activated neurons in WT and KO mice, but 
fewer activated neurons were in PACAP KO animals compared to WT mice. Mean ± SEM; 2-way-ANOVA, 
Bonferroni post-hoc test, ***p < 0.001 vs. WT silent; ++p < 0.01 vs. KO silent; ##p < 0.01, #p < 0.05 vs. WT 
noise. (d) Representative images of Nissl-staining of VCN and DCN of 4-month-old WT and KO mice. (e) Sum 
of the number of neurons in VCN and DCN in WT and KO mice. There was no significant difference between 
WT and PACAP KO animals. Mean ± SEM, Student’s t-test.
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the results than other commonly used anaesthetics (e.g. isoflurane)71,72. Body mass based calculation of anaes-
thetics and the same experimental protocol used for ABR measurements provided equal level of anaesthesia for 
all animals excluding its deteriorating effect on the KO vs. WT comparisons. During the ABR measurement, the 
body temperature was maintained and corneal drying was prevented. ABRs were recorded by an ABR System 3 
workstation (Tucker-Davis Technologies, Alachua, FL). Click (0.4 ms duration) and tone burst (3 ms duration, 
0.2 ms rise/decay; 4.1, 8.2, 16.4, 32.8 and 65.6 kHz) stimuli were generated by the SigGen software package and 
delivered in a closed acoustic system to the external auditory meatus through a plastic tube connected to an 
EC1 electrostatic speaker. Electroencephalograms were recorded with subdermal needle electrodes (Rochester 
Figure 6. Expression of c-Fos in the central relay nuclei of the auditory pathway of 1.5-month-old wild-type 
(WT) and PACAP-deficient (KO) mice after noise exposure (noise) or without noise exposure (silent). (a) 
Superior olivary complex: lateral and medial superior olive (LSO, MSO), and ventromedial and ventrolateral 
periolivary nuclei (VMPN, VLPN). (b) Nuclei of the lateral lemniscus (NLL): representative images with 
lower and higher magnification in frontal sections of the brainstem and numerical analysis. Arrows on the low 
magnification inset show the location of the dorsal part of the NLL. (c) Inferior colliculus (IC). (d) Primary 
auditory cortex (AU1). Noise application caused a significant elevation in the number of activated neurons both 
in WT and KO mice (non-significant in the AU1), but there was no difference between the two genotypes. (a–d) 
Mean ± SEM; 2-way-ANOVA, Bonferroni post-hoc test. ***p < 0.001, **p < 0.01 vs. WT silent; +++p < 0.001, 
++p < 0.01 vs. KO silent.
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Nucleus WT silent WT noise KO silent KO noise
p value
p1 p2 p3
VCN 2.96 ± 0.32 52.95 ± 5.46 3.73 ± 0.36 21.47 ± 8.38 p < 0.0001 p = 0.0012 p = 0.0214
DCN 3.68 ± 1.64 68.23 ± 11.43 2.83 ± 0.72 22 ± 1.73 p < 0.0001 p = 0.0042 p = 0.0012
MSO-LSO 21.24 ± 3.99 63.97 ± 10.54 20.23 ± 7.11 87.6 ± 9.6 p = 0.0096 p = 0.0033 ns
VMPN-VLPN 26.24 ± 4.42 106.38 ± 11.8 32.50 ± 2.84 113.10 ± 5.90 p < 0.0001 p = 0.0007 ns
NLL 29.73 ± 4.16 75.61 ± 8.61 29.73 ± 4.95 89.35 ± 4.90 p < 0.0001 p < 0.0001 ns
IC 104.59 ± 13.8 697.6 ± 178.4 105 ± 33.66 671.33 ± 59.2 p = 0.0019 p = 0.0038 ns
AU1 31.06 ± 4.90 49.85 ± 2.15 38.00 ± 6.21 52.09 ± 8.78 ns ns ns
Table 2. Expression of c-Fos in the nuclei of the auditory pathway of 1.5-month-old wild-type (WT) and 
PACAP-deficient (KO) animals after noise exposure (noise) or without noise exposure (silent). Mean ± SEM. 
VCN, DCN: ventral and dorsal cochlear nuclei, MSO: medial superior olive, LSO: lateral superior olive, VMPN: 
ventromedial periolivary nucleus, VLPN: ventrolateral periolivary nucleus, NLL: nuclei of the lateral lemniscus, 
IC: inferior colliculus, AU1: primary auditory cortex; p1: WT noise vs. WT silent, p2: KO noise vs. KO silent, 
p3: KO noise vs. WT noise; ns = non-significant.
Figure 7. Dissection of the cochlea. (a) External aspect of the intact bony cochlea. (b) Bony wall of the cochlea 
partly removed. Cochlear duct: →; osseus spiral lamina: *. (c) Removal of the apical part of the cochlear duct 
(→). (d) Cochlea broken into two parts for gaining access to the basal part of the cochlear duct (→). (e) The 
main part with the modiolus after removal of the cochlear duct. Osseus spiral lamina: *. (f) The other part of 
the cochlea with the cochlear duct (→). Subsequently this part of the cochlear duct will also be dissected (not 
shown).
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Electro-medical Inc., USA) as the potential difference between an electrode on the vertex (active) and an elec-
trode behind the right pinna (reference). The rear leg served as a ground. Measurements were always performed 
on the right ear. The evoked responses were amplified, and 800 sweeps were averaged in real time. The intensity 
was increased in 10 dB steps from 0 to 80 dB in click stimulation mode. To obtain auditory thresholds at different 
frequencies, the sound intensity of the tone burst stimuli was attenuated in 10 dB steps from 90 to 10 dB. The 
threshold was defined as the lowest intensity at which a visible ABR wave was seen (BioSig software) (Fig. 1/a). 
Numbers of measurements: 29 WT and 26 KO mice at the age of 1.5 month, 18 WT and 15 KO mice at the age of 
4 months and 17 WT and 8 KO mice at the age of 8 months.
Besides measuring the hearing thresholds, we analysed the individual ABR waves evoked by tone burst stimuli 
in a Firebird based custom database in all of the 1.5-month-old mice (n = 29 WT and 26 KO). We identified the 
ABR peaks (peak I to peak V) and measured the amplitudes and latencies for each peak on each measured SPL. 
Peak latencies were determined relative to the onset of the acoustic stimuli and wave amplitudes were calculated 
as the difference between the two values represented by response maxima (peak) and subsequent minima (valley) 
(Figs 2/b, 3/b).
Auditory pathway activation – c-Fos immunolabeling. We performed c-Fos immunolabeling for 
elucidating neuronal activation after white noise application in 1.5-month-old mice (n = 9 WT and 8 KO) in 
the following nuclei of the auditory pathway: VCN, DCN, SOC, NLL, IC and AU173. We placed our mice into a 
closed ventilated “noise box”. Noise exposure (4 to 20 kHz white noise with 100 dB sound pressure, 30 min) was 
generated with the Audacity computer software (Dominic Mazzoni, GNU GPL license) and an amplifier (Mc.
Taatoo, Nightline Pro 400) connected to the PC. The piezo high frequency speaker was located on the ceiling of 
the box. The overall noise level and frequency composition were measured using a calibrated microphone in a 
combination with SVAN971 (SVANTEK SP. Z O.O.) sound level meter. After noise exposure, we allowed 1 hour 
for c-Fos transcription, translation and for its subsequent translocation to the nucleus. In contrast to the noise 
exposed group (labelled as ‘noise’), the control group (labelled as ‘silent’) was held in a silent environment for 
24 hours before termination including a 30 min period in the “noise box” without noise exposure.
Animals were overanesthetized with double-dose intraperitoneal ketamine-xylazine injection. Transcardial 
perfusion was performed by PBS solution (sodium phosphate-buffered saline, 20 ml, 0.1 M, pH 7.4), followed by 
paraformaldehyde fixative (150 ml 4% paraformaldehyde in 0.2 M Millonig sodium phosphate buffer, pH 7.4). 
After decapitation, the dissected brains were postfixed in the same fixative for 24 h, then 30 µm coronal sec-
tions were prepared using a Leica VT1000S vibratome (Leica Biosystems, Wetzlar, Germany). We performed 
free-floating immunohistochemistry with polyclonal rabbit anti-c-Fos antiserum (Santa Cruz Biotechnology Inc., 
sc-52, Santa Cruz, CA, USA, 1:500) followed by biotinylated goat anti-rabbit secondary antibody (Vectastain Elite 
ABC Kit, Vector Laboratories, Burlingame, CA, USA, 1:200)27. For visualization diaminobenzidine (DAB, D5637, 
Sigma-Aldrich, Hungary) was used. For detailed protocol please see Supplementary Information. For evaluation, 
Figure 8. Proteome profile analysis of cochlear duct lysates with R&D Mouse Proteome Profiler Mouse 
Cytokine Array Panel A (a,c) and Mouse Angiogenesis Array Kit (b,d). (a,b) Representative images for Cytokine 
Array Panel A (B1: BLC, B7: CD54, D12: CXCL12) and Angiogenesis Array Kit (A8: TF, B4: DPPIV, B7: 
endostatin, B9: FGF acidic, C8: IGFBP-2, E2: osteopontin, E7: PF4, F4: serpin F1). See Supplementary Table S2 
for identification of all measured proteins. (c,d) Pixel density of protein dots acquired from cochlear duct 
lysates. There were no significant differences in either examined factors between wild-type (WT) and PACAP-
deficient (KO) mice. Mean ± SEM, Student’s t-test.
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a Nicon Microphot FXA microscope was used with a Spot RT colour digital camera (Nikon, Tokyo, Japan). 
Microphotographs were evaluated with ImageJ 1.50i program. For publication purposes, representative images 
were contrasted and in some cases the brightness was adjusted to correct the uneven illumination in peripheral 
areas. Touch-up tools were used to remove technical artefacts (i.e. dye crystals/particles, rests of embedding mate-
rial) from the images (Photoshop 7.0.1, Adobe, San Jose, CA, USA). Digital editing did not influence the scientific 
message of the images.
Cell count measurement - Nissl staining. For cell count measurements, the samples of untreated WT 
and KO animals (n = 3 WT and 3 KO) were fixed and sectioned as described for c-Fos immunolabeling. Then the 
sections were mounted on gelatine-coated glass slides and stained by Nissl (0.5 g Azur III; 0.5 g sodium tetrabo-
rate; 0.5 g toluidine blue; 30 g saccharose in 100 ml distilled water). Excess stain was removed by 96% and absolute 
alcohol. After xylene treatment (10 min), samples were coverslipped with DePex (Fluka, Heidelberg, Germany). 
Digitalization, evaluation and the correction of representative images were performed as described above. Cells 
with well-defined nuclei and nucleoli were counted to exclude glial cells from the measurement. Hearing impair-
ment was similarly present in all three examined age groups (ABR). Therefore, the comparison of cell numbers 
was performed only in 4-month-old WT and KO mice.
Cochlear duct proteome profile analysis. The bony cochlea was dissected from both sides of WT and 
PACAP KO mice (n = 20 WT and 20 KO) and placed in perilymph-like solution (composition in mM: NaCl 
22.5; KCl 3.5; CaCl2 1; MgCl2 1; HEPES.Na 10; Na-gluconate 120; glucose 5.55; pH 7.4; 320 mOsm/l), which was 
continuously oxygenated74. Dissection of the cochlea occurred under operating microscope in the perilymph-like 
solution. The outer bony wall of the cochlea was removed and the apical part of the cochlear duct was sepa-
rated from the modiolus. Then the cochlea was broken into two parts and the remaining part of cochlear duct 
was dissected (Fig. 7). The cochlear ducts were placed in Eppendorf tubes containing PBS buffer with protease 
inhibitor, homogenized with a handheld homogenizer, sonicated on ice for 2 min and centrifuged for 5 min with 
14,000 rpm. Until further work, the samples were stored at −20 °C in the protease inhibitor containing solution. 
The protein concentrations of tissue samples were measured by absorption spectrophotometry. The samples were 
then analysed with R&D Systems Proteome Profiler Mouse Cytokine Array Panel A and Mouse Angiogenesis 
Array Kit (R&D Systems, Biomedica, Hungary) and handled according to the manufacturer’s description. The 
Proteome Profilers are able to detect 40–53 different proteins based on the specific binding between the antibod-
ies (attached to a nitrocellulose membrane) and the proteins in the examined samples (Supplementary Table S2). 
The analyses were performed as described in the previous work of our research group75. Briefly: the samples were 
placed in buffer with 15 μl of primary antibody (1:100) and incubated for 1 h on room temperature. Meanwhile, 
the nitrocellulose membranes were blocked for 1 h. Thereafter, the reconstituted Detection Antibody Cocktail was 
placed on each membrane (1.5 ml pro membrane) and incubated for overnight on a moving platform at 2–8  °C. 
The membranes were washed with PBS for 3 × 10 min, treated with horseradish-peroxidase-conjugated streptavi-
din and washed again for 3 × 10 min in PBS. Then the membranes were treated with 2 ml of chemiluminescence 
detection reagent (Amersham Biosciences, Hungary). On the developed X-ray films the pixel volume of the spots 
correlates with the quantity of the corresponding proteins. The scanned images of the X-ray films were evaluated 
with ImageJ 1.50i software. The pixel volumes were normalized to the positive controls. All measurements arise 
from 2 independent kits providing results from 4 independent measurements (2 membranes per kit were used 
for the same group of animals). All individual samples contained the cochlear duct homogenates of 5–5 animals. 
Representative images were corrected to obtain optimal contrast (Photoshop 7.0.1, Adobe, San Jose, CA, USA). 
Hearing impairment was similarly present in all three examined age groups (ABR). Therefore, comparison of 
proteome profiles was performed only in 3–6-month-old WT and KO mice.
Statistical analysis. Two-way ANOVA was performed and followed by Bonferroni post-hoc test for ABR 
hearing threshold, amplitude and latency as well as for c-Fos immunolabeling measurements. The homogeneity of 
variance as well as the normal distribution of datasets subjected to ANOVA was verified by Bartlett’s Chi-square 
and Shapiro-Wilk test, respectively. Two-tailed Student’s t-test was performed for Nissl staining and proteome 
profile analysis measurements. ‘N-1’ Chi-squared test was performed for the occurrence of peak IV measure-
ments. Alpha level was 0.05 for all tests. Values are given as mean ± SEM. Statistica v8.0 (StatSoft Inc., USA), 
Prism 6.1 (GraphPad Software, USA) and Microsoft Excel (Microsoft Corporation, USA) were used for statistical 
analysis.
Data Availability
The datasets and original digital images generated during and/or analysed during the current study are available 
from the corresponding authors on reasonable request.
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